[1]陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89-92.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
　TAO Lin.Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy[J].,2023,52(1):89-92.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
点击复制

原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年1期
页码:
89-92
栏目:
药物与临床
出版日期:
2023-01-05

文章信息/Info

Title:
Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy
作者:
陶 琳
(商洛市中心医院感染性疾病科,陕西 商洛 726000)
Author(s):
TAO Lin
(Department of Infectious Diseases,Shangluo Central Hospital,Shangluo 726000,China)
关键词:
原发性肝癌;  肝动脉化疗栓塞术;  抗菌药物;  继发感染;  危险因素
Keywords:
Primary liver cancer;  TACE;  Antibiotics;  Secondary infection;  Risk factor
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2023.01.021
文献标志码:
A
摘要:
目的:探究原发性肝癌患者术后抗菌药物的应用情况,同时分析患者术后继发感染的危险因素,进而控制相关危险因素而降低术后感染的风险。方法:选取采用肝动脉化疗栓塞术(TACE)进行治疗的120例原发性肝癌患者作为研究对象,并根据其术后是否发生感染将其分为感染组(33例)和非感染组(87例)。①记录所研究对象的性别、年龄、体重指数(BMI)、有无吸烟史等一般资料,同时记录患者CTP分级、是否合并肝硬化、是否合并糖尿病、是否存在肝外转移、是否有胸腔积液、肿瘤数目等疾病情况; ②术前测定患者血清白蛋白(Alb)、白细胞计数(WBC)、血红蛋白(Hb)水平; ③记录术后患者抗菌药物的使用情况; ④记录患者术后继发感染的发生情况,并对相关危险因素进行分析。结果:所有原发性肝癌患者在TACE术后共使用386次抗菌药物,其中应用一代头孢菌素243次(62.95%),二代头孢菌素56次(14.51%),三代头孢菌素63次(16.32%),氟喹诺酮类24次(6.22%); 术后发生继发感染的患者33例,未感染患者87例,感染率达到27.50%,其中切口感染12例(36.36%),肺部感染6例(18.18%),血流感染5例(15.15%),腹膜炎6例(18.18%),泌尿感染4例(12.12%); Logistic回归分析结果显示,有吸烟史、CTP评分高、合并肝硬化、合并糖尿病、合并肝外转移、有胸腔积液、高水平白细胞计数、低水平血清白蛋白、低水平血红蛋白均是患者术后继发感染的独立危险因素(均P<0.05)。结论:临床上采用TACE术治疗原发性肝癌患者时,需加强抗菌药物的监管,规范抗菌药物的应用。有吸烟史、CTP评分高、合并肝硬化、合并糖尿病、合并肝外转移、有胸腔积液、高水平白细胞计数、低水平血清白蛋白、低水平血红蛋白均是患者术后继发感染发生的独立危险因素,临床上应对以上各因素采取相应的预防措施进行干预,以降低患者术后继发感染的发生率,提高TACE手术治疗的安全性和有效性。
Abstract:
Objective:To explore the application of postoperative antibiotics in patients with primary liver cancer,and to analyze the risk factors of postoperative secondary infection in patients,so as to control the relevant risk factors and reduce the risk of postoperative infection.Methods:A total of 120 patients with primary liver cancer who were treated with TACE were selected and divided into infection group(33 cases)and non-infection group(87 cases)according to whether postoperative infection occurred.General data on sex,age,body mass index(BMI),smoking status,CTP grade,and presence or absence of cirrhosis,presence or absence of diabetes mellitus,presence or absence of extrahepatic metastases,presence or absence of pleural effusions,and number of tumors were recorded.The levels of serum albumin,white blood cell count and hemoglobin were measured before surgery.The use of antibiotics in postoperative patients and the occurrence of postoperative secondary infection were recorded,and the related risk factors were analyzed.Results:All patients with primary liver cancer received a total of 386 antibiotics after TACE,including 243 first-generation cephalosporins(62.95%),56 second-generation cephalosporins(14.51%),63 third-generation cephalosporins(16.32%),and 24 fluoroquinolones(6.22%).There were 33 patients with secondary infection and 87 uninfected patients,the infection rate reached 27.50%,including 12 cases of incision infection(36.36%),6 cases of lung infection(18.18%),5 cases of bloodstream infection(15.15%),6 cases of peritonitis(18.18%),and 4 cases of urinary infection(12.12%).Logistic regression analysis showed that smoking history,high CTP score,liver cirrhosis,diabetes mellitus,extrahepatic metastasis,pleural effusion,high white blood cell count,low serum albumin,and low hemoglobin were all independent risk factors for postoperative secondary infection(all P<0.05).Conclusion:When TACE is used in clinical treatment of patients with primary liver cancer,it is necessary to strengthen the supervision of antibacterial drugs and standardize the application of antibacterial drugs.smoking history,high CTP score,liver cirrhosis,diabetes mellitus,extrahepatic metastasis,pleural effusion,high white blood cell count,low serum albumin,and low hemoglobin were all independent risk factors for postoperative secondary infection.Corresponding preventive measures should be taken clinically to intervene the above factors to reduce the incidence of postoperative secondary infection and improve the safety and effectiveness of TACE surgical treatment.

参考文献/References:

[1] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[2] 周泽文,刘颖春,向邦德,等.原发性肝癌的全球展望:流行情况、危险因素和人群归因分值[J].中国癌症防治杂志,2021,13(1):14-21.
[3] 孟唤男,赵 丽,刘 柳,等.中西医结合防治原发性肝癌研究进展[J].中医药学报,2021,49(2):115-119.
[4] 胡 峻,高月求,孙学华,等.肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌近期疗效研究[J].陕西中医,2020,41(9):1237-1240.
[5] 王宇翾.原发性肝癌患者综合治疗的研究进展[J].中国疗养医学,2020,29(8):817-819.
[6] 李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,42(6):728-731.
[7] 韦小妹,张名林,张 金,等.肝癌介入化疗患者医院感染的病原菌分布及影响因素分析[J].中华医院感染学杂志,2018,28(17):2621-2624.
[8] 李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,48(7):873-875.
[9] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华肝脏病杂志,2020,28(2):112-128.
[10] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320.
[11] 谭 妮,郑海平,欧 超.肝癌根治术治疗原发性肝癌患者的术后生存率及预后影响因素分析[J].现代肿瘤医学,2019,27(5):826-829.
[12] 周劲梅,杨银山,黄 明,等.肝癌介入化疗栓塞术预防性使用抗菌药物的临床分析[J].中国医药指南,2017,15(24):20-21.
[13] 蔡妙甜,梁连春.原发性/转移性肝癌患者经肝动脉化疗栓塞术或消融术后发生肝脓肿的病原菌分布及耐药性分析[J].临床肝胆病杂志,2020,36(1):118-122.
[14] 程月召,薛 昀.肝癌肝动脉化疗栓塞术45例术后发热用药的药学监护[J].药品评价,2021,18(10):594-597.
[15] 王世材,于世平,李玲玲,等.TACE联合栓塞治疗中晚期肝癌合并肝动脉-门静脉瘘[J].中国介入影像与治疗学,2019,16(12):721-725.
[16] 刘 翠,赵 艳.健康信念指导下的中西医结合优质护理干预提高原发性肝癌 TACE 术后的依从性和生活质量[J].现代肿瘤医学,2019,27(22):4018-4022.
[17] 段惠龙.不同介入栓塞化疗方案联合射频消融治疗原发性肝癌疗效及对患者免疫功能的影响[J].陕西医学杂志,2018,47(10):1303-1305.
[18] 施一翔,刘敬禹,江 旭,等.肝癌行肝动脉化疗栓塞术后并发肝脓肿的危险因素和治疗策略[J].海军医学杂志,2018,39(5):444-447.
[19] 王艺歆,刘 英,王海荣,等.肝癌 TACE 术后感染的危险因素及血清 IL-8 与CRP和 PCT 对感染的诊断价值[J].中华医院感染学杂志,2019,29(10):1495-1499.
[20] 秦喜竹,王小二,高晨琛,等.肝癌肝动脉化疗介入术后继发感染的危险因素研究[J].现代消化及介入诊疗,2020,25(4):518-521.
[21] 姜敏霞,陈旭高,姚红响,等.肝癌肝动脉化疗栓塞术后发生感染影响因素分析[J].介入放射学杂志,2018,27(2):133-136.

相似文献/References:

[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.
[2]李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,(7):873.
　LI Xun,ZHANG Xianglin..Efficacy observation and TSGF change in primary hepatocellular carcinoma by TACE and entecavir[J].,2019,(1):873.
[3]刘立友,吴东洋,蔡青山,等.原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J].陕西医学杂志,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
　LIU Liyou,WU Dongyang,CAI Qingshan,et al.Expression of LAMA3 and FAK proteins in primary liver cancer and their relationship with clinicopathological features and prognosis of patients[J].,2023,52(1):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
[4]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
　LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(1):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
[5]李晓勤,王 群,何晓兰,等.多模式镇痛对原发性肝癌患者休斯顿疼痛情况调查表评分及血清结合珠蛋白水平的影响[J].陕西医学杂志,2024,(4):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
　LI Xiaoqin,WANG Qun,HE Xiaolan,et al.InfLuences of multimodal analgesia on HPOI score and serum haptoglobin level in patients with hepatocellular carcinoma[J].,2024,(1):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
[6]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNA JPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
　MENG Fangang,LIU Wenyu,ZHEN Lijun,et al.Expression levels of long non-coding RNA JPX and microRNA-371a-5p in primary liver cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(1):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基金资助项目(53017952)
更新日期/Last Update: 2022-12-28